Genelux Corporation (GNLX)
GNLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.52
-0.98% on the day
Market cap
$114.0M
Micro cap
Revenue · 2025
$8K
0.0% on 2024
Net income · 2025
-$32.1M
-401812.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | GNLX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001231457 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8K |
| Net income | -$32.1M |
| Operating income | -$33.2M |
| Net margin | -401812.5% |
| Operating margin | -415175.0% |
| Revenue growth | 0.0% |
| Cash | $5.3M |
| Total assets | $19.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 14252.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-19 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-06-22 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 358 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HURA | TuHURA Biosciences Inc. | $1.81 | -4.74% | $115.3M |
| PDSB | PDS Biotechnology Corporation | $1.60 | +5.26% | $116.0M |
| SPRB | Spruce Biosciences Inc. | $40.35 | -5.88% | $116.0M |
| VTVT | vTv Therapeutics Inc. | $28.23 | -7.32% | $111.6M |
| NRXP | NRX Pharmaceuticals Inc. | $2.70 | -5.26% | $116.9M |
| CLLS | Cellectis S.A. | $1.10 | -6.78% | $110.6M |
| FHTX | Foghorn Therapeutics Inc. | $1.85 | -5.13% | $109.9M |
| NERV | Minerva Neurosciences Inc | $2.52 | -12.98% | $120.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier